The observed treatment failure in melanoma patients was found to result from BRAF/MEK-inhibitor-induced activation of the SEMA6A/RhoA/YAP axis as consequence of the crosstalk between tumor and stromal cells [72]. This evidence concerns the gene BRAF and neoplasm.